Mackenzie Financial
RIGL icon

Mackenzie Financial’s Rigel Pharmaceuticals RIGL Stock Holding History

Mackenzie Financial’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$701K Sell
17,922
-10,900
-38% -$336K ﹤0.01% 1250
2026
Q1 		$779K Buy
28,822
+5,160
+22% +$173K ﹤0.01% 1130
2025
Q4 		$1.01M Sell
23,662
-5,630
-19% -$212K ﹤0.01% 1053
2025
Q3 		$830K Sell
29,292
-8,535
-23% -$255K ﹤0.01% 1115
2025
Q2 		$709K Buy
+37,827
New +$717K ﹤0.01% 1112
2024
Q2 		– Sell
-4,767
Closed -$70.6K – 1609
2024
Q1 		$70.6K Buy
4,767
+1,279
+37% +$17.2K ﹤0.01% 1460
2023
Q4 		$50.6K Buy
3,488
+176
+5% +$1.8K ﹤0.01% 1446
2023
Q3 		$33.8K Buy
3,312
+402
+14% +$4.84K ﹤0.01% 1436
2023
Q2 		$38.1K Hold
2,910
– – ﹤0.01% 1476
2023
Q1 		$38.4K Sell
2,910
-475
-14% -$7.55K ﹤0.01% 1458
2022
Q4 		$50.8K Buy
3,385
+351
+12% +$3.22K ﹤0.01% 1352
2022
Q3 		$36K Sell
3,034
-459
-13% -$6.21K ﹤0.01% 1383
2022
Q2 		$39K Buy
3,493
+1,496
+75% +$30K ﹤0.01% 1410
2022
Q1 		$60K Hold
1,997
– – ﹤0.01% 1365
2021
Q4 		$53K Sell
1,997
-73
-4% -$2.2K ﹤0.01% 1398
2021
Q3 		$75K Buy
2,070
+417
+25% +$16.4K ﹤0.01% 1386
2021
Q2 		$72K Buy
1,653
+583
+54% +$22K ﹤0.01% 1207
2021
Q1 		$37K Sell
1,070
-140
-12% -$5.54K ﹤0.01% 1117
2020
Q4 		$42K Hold
1,210
– – ﹤0.01% 1029
2020
Q3 		$29K Sell
1,210
-200
-14% -$4.91K ﹤0.01% 977
2020
Q2 		$26K Buy
+1,410
New +$25.4K ﹤0.01% 995
2018
Q2 		– Sell
-7,718
Closed -$273K – 1050
2018
Q1 		$273K Buy
7,718
+1,312
+20% +$52.5K ﹤0.01% 828
2017
Q4 		$249K Buy
6,406
+1,909
+42% +$72.7K ﹤0.01% 779
2017
Q3 		$114K Buy
4,497
+646
+17% +$15.7K ﹤0.01% 611
2017
Q2 		$105K Buy
3,851
+2,151
+127% +$58.9K ﹤0.01% 608
2017
Q1 		$56K Buy
+1,700
New +$43.3K ﹤0.01% 629

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's RIGL Position: Q2 2026 in Review

Mackenzie Financial reduced its Rigel Pharmaceuticals (RIGL) stake by 38% in Q2 2026, selling an estimated $336K and leaving 17,922 shares worth $701K. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

Mackenzie Financial first reported a position in RIGL in Q1 2017 and has held it in 26 quarters since. The position peaked at $1.01M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Mackenzie Financial held 17,922 shares of Rigel Pharmaceuticals worth $701K as of Q2 2026.
  • Mackenzie Financial sold 10,900 Rigel Pharmaceuticals shares in Q2 2026, an estimated $336K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1250 holding.
  • Mackenzie Financial first reported a position in Rigel Pharmaceuticals in Q1 2017 and has held it in 26 quarters since.
  • Mackenzie Financial's Rigel Pharmaceuticals position peaked at $1.01M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.